1-tert-butyl-3-(2-naphthalenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-tert-butyl-3-(2-naphthalenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
• 英文别名: 2NM-PP1；4-amino-1-(tert-butyl)-3-(2'-naphthylmethyl)pyrazolo[3,4-d]pyrimidine；1-tert-Butyl-3-naphthalen-2-ylmethyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine；1-tert-butyl-3-(naphthalen-2-ylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
• 化学式: C₂₀H₂₁N₅
• 分子量: 331.42
• InChiKey: MHCAHEOZFDJGMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  69.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• INHIBITION OF ALPHA-SYNUCLEIN TOXICITY
  申请人：Lindquist Susan L.

  公开号：US20100273776A1

  公开（公告）日：2010-10-28

  Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are a symptom or cause of the disease.

  提供了用于治疗或缓解α-突触核蛋白毒性、α-突触核蛋白介导的疾病或α-突触核蛋白纤维是疾病的症状或原因之一的化合物和组合物。
• MODULATION OF PROTEIN TRAFFICKING
  申请人：Bulawa Christine Ellen

  公开号：US20100331297A1

  公开（公告）日：2010-12-30

  Compounds and compositions are provided for treatment or amelioration of one or more disorders characterized by defects in protein trafficking. A method of treating a disorder characterized by impaired protein trafficking includes administering to a subject or contacting a cell with a compound of Formula I: [formula here] or pharmaceutically acceptable salts or derivatives thereof.

  本发明提供用于治疗或改善由蛋白质运输缺陷所特征的一个或多个疾病的化合物和组合物。一种治疗由蛋白质运输受损所特征的疾病的方法包括向受试者施用或与细胞接触化合物I的药物或其药学上可接受的盐或衍生物。[公式在此]
• High affinity inhibitors for target validation and uses thereof
  申请人：Princeton University

  公开号：EP1321467A2

  公开（公告）日：2003-06-25

  An inhibitor that does not inhibit a catalytic activity of a wild-type protein kinase but inhibits the same catalytic activity of the corresponding mutant protein kinase, wherein the wild-type protein kinase and the mutant protein kinase are functionally similar.

  一种抑制剂，它不能抑制野生型蛋白激酶的催化活性，但能抑制相应突变型蛋白激酶的相同催化活性，其中野生型蛋白激酶和突变型蛋白激酶在功能上相似。
• Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
  申请人：University of Washington through its Center for Commercialization

  公开号：US10544104B2

  公开（公告）日：2020-01-28

  Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii (T. gondii) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, wherein the variables X, Y, Z, L, R1, and R3 are defined herein.

  本发明描述了治疗由传染性真核寄生虫弓形虫（T. gondii）引起的弓形虫病和治疗由传染性真核寄生虫副隐孢子虫（C. parvum）和原隐孢子虫（C. hominus）引起的隐孢子虫病的组合物和方法。特别是，本公开涉及使用式中的吡唑嘧啶和/或咪唑并[1,5-a]吡嗪抑制剂抑制刚地隐孢子虫钙依赖性蛋白激酶（TgCDPKs）或副隐孢子虫和人隐孢子虫钙依赖性蛋白激酶（CpCDPKs）的组合物和方法、 其中变量 X、Y、Z、L、R1 和 R3 在本文中定义。
• HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF
  申请人：Princeton University

  公开号：EP1140938B1

  公开（公告）日：2003-08-27